• Advisory Board Member, Janssen Pharmaceuticals, 2016
• Consultant, Boehringer Ingelheim, 2017

• Member of Clinical Foundations (Lead Serve Inspire Part 1) Academic Program Committee, The Ohio State College of Medicine, 2016-2017
• Chair of Standardized Letter of Recommendation work group for American Academy of Dermatology, 2016-2017
• Member of Poster Exhibit Task Force for American Academy of Dermatology, 2016-2018 
• Faculty chair for the Dermatology Interest Group Ohio State University, 2014- current

• Invited contributor to American Academy of Dermatology’s Board Prep Question Bank for blistering diseases and connective tissues disorders, 2017

• Does the SLOR impact resident match? Dermatology Teachers Exchange Group at Association of Professors of Dermatology Meeting. Chicago, IL. Chicago, IL 60 meeting attendees., Oct 2017
• Give me a Hand! Ohio Dermatological Association annual meeting Resident Day. Columbus, OH. 60 dermatology residents., Sept 2017
• Psoriasis 2017: News you can use. Penn State Young Faculty Lecture Series. Hershey, PA. 20 residents and attendings., March 2017
• Managing the depth of psoriatic disease from the inside out: new options for psoriasis and psoriatic arthritis patients. Ohio Dermatological Association annual meeting. Columbus, OH. 100-110 dermatologists., Oct 2016
• Implementation of a Dermatology Standardized Letter of Recommendation. Dermatology Teachers Exchange Group at Association of Professors of Dermatology Meeting. Chicago, IL. Chicago, IL 60 meeting attendees., Oct 2016
• Time to “scale” new heights in psoriasis: an update on management with medication and diet. Ohio State Dermatology Grand Rounds. Columbus, OH. 50-60 dermatologists., Sept 2016
• Standardized Letter of Recommendation – Pros and Cons.  Association of Dermatology Professors. Chicago, IL. 150 meeting attendees, Oct 2015
• Blistering Disease Tests: What are the “DIF”ferences? Ohio State Dermatology Grand Rounds. Columbus, OH. 50-60 dermatologists, Feb 2015
• Common Rashes in Primary Care, CME Webcast lecture. The Ohio State University. Audience: Physicians who subscribe to lecture series for CME credit and education, Oct 2014
• Cutaneous Collagenous Vasculopathy. Gross and Microscopic Dermatology Symposium at American Academy of Dermatology. Denver, CO. Audience: 50-60 meeting attendees, March 2014
• Diagnostic tests for blistering diseases. Penn State Dermatology Grand Rounds. Hershey, PA. Audience: 50-60 dermatologists, Dec 2014
• Spaced repetition: an under-utilized tool in medical education
  Dermatology Teachers Exchange Group at Association of Professors of Dermatology Meeting. Chicago, IL. Audience: 200 dermatology chairs and program directors, Sept 2013
• African Tick Bite Fever. Penn State Dermatology: State-of-the-Art Issues. Hershey, PA. Audience: 100 academic and community dermatologists, April 2013
• African Tick Bite Fever. Gross and Microscopic Dermatology Symposium at American Academy of Dermatology. Miami, FL. Audience: 50-60 meeting attendees, March 2013

• Associate Editor for BioMed Central (BMC) Cancer, 2016-current 
• Reviewer for Journal of the American Academy of Dermatology, 2014- current
• Reviewer for Journal of the American Academy of Dermatology Case Reports, 2014- current

• Dermatology Therapeutics.  Lecture to MSIV class, April 2015
• Provide biweekly one hour long medical student lectures for rotating medical students, Jan 2015-current (biweekly)
• Career exploration in Dermatology. Twice a year - lecture to group of MSI students interested in dermatology, Jan 2015- current (every 6 months)
• Inflammatory Disorders in Dermatology.  Yearly lecture to MSI class, Nov 2014-current (yearly)

• Spohn G, Kaffenberger J. “Blister in the sun”: a case of bullous phytophotodermatitis. Ohio Dermatological Conference, Sept 2017.
• Pettit C, Ulman C, Spohn G, Kaffenberger J. A case of segmental Darier disease treated with doxycycline monotherapy. Ohio Dermatological Conference, Sept 2017.
• Ferris GJ, Fabbro S, Gru A, Kaffenberger J. Xanthomatized neutrophilic dermatosis in a patient with myelodysplastic syndrome. Ohio Dermatological Conference, Oct 2016. Columbus, OH
• Kaffenberger J. Implementation of a Dermatology Standardized Letter of Recommendation. Poster presented at Dermatology Teachers Exchange Group, Oct 2016. Chicago, IL
• Dean A, Hasan F, Kaffenberger J. 51 year-old female with multicentric reticulohistiocytosis. Ohio Dermatological Conference, Oct 2015. Columbus, OH
• Donnelly K, Tyler K, Peters S, Carr R, Kaffenberger J. Herpetic infection complicating Hailey-Hailey Disease: A case report and review of the literature. Ohio Dermatological Conference, Oct
• 2015. Columbus, OH
• Ferris GJ, Spohn GP, Gru A, Kaffenberger J. Mucin in the dermis: a case of tender tumors. Ohio Dermatological Conference, Oct 2015. Columbus, OH
• Morse M, Fabbro S, Gru A, Kavran C, Kaffenberger J. Familial granuloma annulare: A case report of 2 siblings. Ohio Dermatological Conference, Oct 2015. Columbus, OH
• Grgurich E, Wagener M, Purcell S, Chung C, Kaffenberger J. Annular atrophic connective tissue panniculitis case. Atlantic Dermatological Conference, April 2015. Philadelphia, PA.
• Kaffenberger J, Kirby J. Spaced repetition: An under-utilized tool in medical education. Poster presented at Dermatology Teachers Exchange Group, Sept 2013. Chicago, IL.
• Yankura JA, Saddic N, Jones CR, Adams DR. Methotrexate-induced UV Reactivation in a Patient with Acute Lymphoblastic Leukemia. Poster presented at Orlando Dermatology Aesthetic and
• Clinical Conference, Jan 2012. 
• Yankura J, French A, Rogawski MA, Hartman A, Gasior M. Assessment of the role of glucose deprivation in the ketogenic diet with 2-deoxyglucose.Epilepsia 2006; 47(suppl 4):338–339. Poster presented at the American Epilepsy Society meeting, Dec 2006.
• Gasior M, Yankura J, French A, Yonekawa W, Hartman A, Rogawski MA. Anticonvulsant Effects of 1,3 Butanediol, a Metabolic Precursor of Ketone Bodies. Epilepsia 2006; 47(suppl 4): 214. Poster presented at the American Epilepsy Society meeting, Dec 2006 and Winter Conference on Brain Research, Jan-Feb 2007.

1. Kaffenberger J. Dermatology Practice Update commentary regarding “The role of adjuvant therapy in pemphigus”. July 8, 2015.  http://www.practiceupdate.com/content/the-role-of-adjuvant-therapy-in-pemphigus/26891/12/4/1

2. Kaffenberger J. Dermatology Practice Update commentary regarding “Clinical and immunologic features of recurrent herpes zoster”. August 25, 2016. https://www.practiceupdate.com/content/clinical-and-immunologic-features-of-recurrent-herpes-zoster/42938/37/4/1

1. Pettit, CJ, Ulman C, Spohn G, Kaffenberger J. A case of segmental Darier disease treated with doxycycline monotherapy. Accepted Jan 4, 2018. Derm Online J. Pending publication (planned March 2018).

2. Wang RF, Zhang M, Alloo A, Stasko T, Miller J, Kaffenberger J. Characterization of the 2016-2017 dermatology standardized letter of recommendation. JCAD. 2018; 11(3): 26-29.

3. Wang RF, Kaffenberger BH, Kaffenberger J. A retrospective review of new-onset dermatitis in patients 60 years or older. JCAD. 2018; 11(1):19-20.

4. Wang RF, Zhang M, Kaffenberger J. Does the dermatology standardized letter of recommendation impact applicants matching into residency? JAAD. 2017; 77(5):e139-e140.

5. Milam P, Korman A, Kaffenberger J. Frequent skin exams in patients with actinic keratoses: the ethical, financial and moral implications. JAAD. 2017;77 (5): 985-987.

6. Milani-Nejad N, Zhang M, Kaffenberger J. The association of bullous pemphigoid and neurological disorders: a systematic review. Eur J Dermatol. 2017 Oct; 27(5):472-481.

7. Yanes D, Kaffenberger J, Carr D. Erythema multiforme as a reaction to imiquimod 5% cream. Derm Online J. 2017; 23(2).

8. Morse M, Gru A, Kaffenberger J. A 64 year old woman with an atrophic plaque on the thigh- Cover question. Am J of Dermpath. 2017; 39(1):45-46.

9. Morse M, Gru A, Kaffenberger J. A 64 year old woman with an atrophic plaque on the thigh- Discussion. Am J of Dermpath. 2017; 39(1): 62-63.

10. Ferris GJ, Fabbro S, Gru AA, Kaffenberger J. Xanthomatized neutrophilic dermatosis in a patient with myelodysplastic syndrome. Am J of Dermpath. 2017;39(5):384-387.

11. Ferris GJ, Spohn GP, Gru A, Kaffenberger J. Mucin in the dermis: a case of tender tumors.  Derm Online J. 2016; 22(8):10.

12. Donnelly KM, Ferris LK, Kaffenberger J. A systematic review of concomitant bullous pemphigoid and psoriasis. J of Psoriasis and Psoriatic Arthritis. 2016; 1(4):150-158.

13. Kaffenberger J, Mosser J, Lee G, Pootrakul L, Harfmann K, Fabbro S, Fernandez Faith E, Carr D, Plotner P, Zirwas M, Kaffenberger B. A retrospective analysis comparing the new standardized letter of recommendation in dermatology with the classic narrative letter of recommendation. J Clin Aesthet Dermatol. 2016; 9(9):36-42.

14. Kaffenberger B, Kaffenberger JA, Wong H, Levin D, Jarjour W, Bechtel M. Magnetic Resonance Elastography and Transient Elastography as a non-invasive analysis for liver fibrosis: can they obviate the liver biopsy in psoriasis patients treated with methotrexate? Int J of Derm. 2015; 54(7):752-756.

15. Kaffenberger J, Helm K, Travelute C. Multiple flesh-colored papules and plaques on the trunk. JAAD. 2015; 72(1):e15-e16.

16. Kaffenberger J, Basak SA, Ioffreda M. Autologous graft-versus-host disease in a child with stage IV neuroblastoma. Pediatr Dermatol. 2015; 32(2):276-279.

17. Kaffenberger B, Kaffenberger J, Zirwas M. A survey of academic dermatologists on the value of residency letters of recommendation. JAAD. 2014; 71(2):395-396.

18. Kaffenberger, JA, Sciacca Kirby J. Lichen Myxedematosus. Treatment of Skin Disease, 4th ed. Ed: Lebwohl, Heymann, Berth-Jones, Coulson. Elsevier, 2014. 388-390.

19. Kaffenberger JA, Helm K. Diffuse telangiectasias on the lower extremities. JAMA Dermatol. 2014; 150(4):451-452.

20. Yankura, JA, Ioffreda M. Necrotic Plaques in a Traveler. JAAD. 2014; 70(5):959-961. 

21. Kaffenberger J, Helm K, Miller, J. Periorbital lupus-like presentation of graft-versus-host disease. Accepted Aug 22, 2014. Cutis. Pending publication

22. Yankura JA, Saddic N, Jones CR, Adams DR. Methotrexate-induced UV Reactivation in a Patient with Acute Lymphoblastic Leukemia. Cutis. 2012 May; 89(5):233-6.

23. Gasior M, Yankura JA, Hartman AL, French A, Rogawski MA. Anticonvulsant and Proconvulsant Actions of 2-Deoxy-D-glucose. Epilepsia. 2010 August; 51(8):1385-94.

24. Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of Hidradenitis Suppurativa with Etanercept Injection. Arch Dermatol. 2010 May;146(5):501-4.

25. Yankura JA, Marks JG Jr, Anderson BE, Adams DR. Spa Contact Dermatitis. Dermatitis. 2008 Mar-Apr;19(2): 100-1.

• Development of multi-disciplinary psoriasis and psoriatic arthritis clinic, 2016
• UVB protocol, restructured time frame for renewal and expiration, 2014
• Biologic laboratory monitoring guidelines, standardized recommendations for department, 2013
• Pigmented lesions guidelines, standardized recommendations for department, 2013

• Principal investigator: Coca-Cola critical difference for women grant for research on women, gender and gender equity for “Investigating the role of providing longer acting reversible contraceptives to patients on isotretinoin in a dermatology outpatient clinic” (7/1/2018 until 6/30/2019) Awarded $3,536
  2018-2019
• Co-principal investigator: Strategic Pharma-Academic Research Consortium (SPARC) Award for “Gene expression and microbiome profiling in Hidradenitis Suppurativa to identify immunological biomarkers of disease activity” (1/1/2017 until 12/31/2018). Collaboration with Washington University in St. Louis. $400,000 total, $119,102 awarded to OSU site. FTE 0.05%.
  2017-2018
• Principal investigator: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab administered concomitantly with topical corticosteroids in patients 6 to 12 years of age with severe atopic dermatitis. R668-AD-1652.
  2017 –current
• Co-investigator: 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Acute Cutaneous Lupus Erythematosus with or without Systemic Manifestations (LILAC). NCT02847598.
  2017- current
• Principal investigator: A Phase 3, multicenter, randomized, double-blind study evaluating the comparative efficacy of CNTO 1959 (Guselkumab) and secukinumab for the treatment of moderate to severe plaque-type psoriasis (ECLIPSE). Clinical Trial CNTO1959PSO3009
  2017- current
• Principal investigator: Multicenter, double-blind, randomized, placebo-controlled study to evaluate safety, tolerability, and efficacy of ixekizumab in patients from 6 to less than 18 years of age with moderate-to-severe plaque psoriasis. Clinical Trial I1F-MC-RHCD.
  2017- current
• Phase 3, randomized, double-blind, study comparing ABT-494 to placebo and to adalimumab in subjects with active psoriatic arthritis who have a history of inadequate response to at least one non-biologic disease modifying anti-rheumatic drug (DMARD). M15-572.
  2017- current
• Principal investigator: A multicenter, randomized,double-blind,parallel group comparison of halobetasol propionate foam, 0.05% versus vehicle foam in subjects with plaque psoriasis. Clinical Trial TI 12209551-310
  2016-2017
• Principal investigator: A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis (CLARITY). Clinical Trial CAIN457A2326
  2016- current
• A randomized, double-blind, placebo-controlled and delayed-start study of LY3314814 in mild Alzheimer’s Disease dementia (Daybreak study). Clinical Trial ID NCT02783573
  2016 – current
• Principal investigator: The Corrona psoriasis registry. 8 year registry to study the comparative safety of approved psoriasis therapies. Clinical Trial Corrona.
  2015- current
• Principal investigator: A phase 3, multicenter, randomized, double-blind, placebo and active comparator-controlled study evaluating the efficacy and safety of guselkumab for the treatment of subjects with moderate to severe plaque-type psoriasis with randomized withdrawal and retreatment (VOYAGE 2). Clinical Trial CNTO1959-PSO3002
  2015-current
• Principal investigator: A prospective, observational study to estimate the proportion of subjects with plaque psoriasis who achieve complete clearance on biologics. Clinical Trial 20120363
  2015-current
• Principal investigator: A 10-year, post-marketing, observational registry of Humira (Adalimumab) in adult patients with chronic plaque psoriasis. Clinical Trial P10-023
  2015-current
• Principal investigator: A multicenter, open registry of patients with psoriasis who are candidates for systemic therapy including biologics. Clinical Trial C0168Z03
  2015- current
• Principal investigator: Investigating the role of providing longer acting reversible contraceptives to patients on isotretinoin in a dermatology outpatient clinic. IRB protocol 2014H0446
  2015-current
• Principal investigator: A phase 3 study to evaluate the efficacy and safety of induction and maintenance regimens of brodalumab compared with placebo and ustekinumab in subjects with moderate to severe plaque psoriasis: AMAGINE-2. Clinical Trial 20120103
  2015-2016
• Principal investigator: A randomized double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab (GP2017) and Humira in patients with moderate to severe chronic plaque-type psoriasis. Clinical Trial GP17-301
  2015-2016
• Principal investigator: A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the efficacy of subcutaneous secukinumab [300 mg] as assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of treatment, compared to placebo, and to assess safety and tolerability up to 24 weeks in adult subjects with moderate to severe scalp psoriasis. Clinical Trial CAIN457
  2015-2016
• Principal investigator: A phase 3 open-label study of the safety and efficacy of adalimumab in subjects with moderate to severe HS. Clinical Trial M12-555
  2015-2016
• Sub-Investigator: A 24-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy, safety, tolerability, biomarker, and pharmacokinetic study of AZD3293 in early Alzheimer’s disease (the AMARANTH study). Clinical Trial D5010C00009
  2015-current
• Sub-Investigator: Multicenter study of the relative importance and impact of lifestyle factors on career choice, Protocol IRB 38505EM
  Funding:
  $3,210 Woodward Endowment for Medical Sciences Education Grant
  $1,000 James Marks Endowment fund and Dept of Dermatology funds
  2011-2015
• Sub-Investigator: Multicenter study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa, Clinical Trial M11-313
  2011-2014
• Postbaccalaureate Intramural Research Training Award (IRTA) Fellow: Investigating the role of glutamate receptors and acetone precursors in epileptic seizures. National Institute of Neurological Disorders and Stroke, Bethesda MA
  2005-2006

• Peak into personality.  Personality assessment to help mitigate conflict., Nov 2017
• Dermatology coding 101, July 2015- current (yearly)
• Psoriasis and recent updates, July 2015-current (yearly)
• Blistering diseases, July 2015- current (yearly)
• Power of the presentation, Part I: A dynamic delivery, May 2017
• Power of the presentation, Part II: Pearls of the powerpoint, Sept 2017

• Co-leader of Ohio State Medical Student Learning Community – Lead monthly 1-2 hour long meetings with 12 medical students on various topics, 2014-current
• Bethesda Mission Free Clinic, 2011-2014
• Penn State Hershey annual free cancer screenings, 2012- 2014
• Camp Horizon – camp counselor for week long camp for kids with dermatological diseases, 2012
• Camp JRA – camp counselor for week long camp for kids with rheumatologic diseases, 2009